MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
MediWound (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, has scheduled its Fourth Quarter and Full Year 2024 financial results release for Wednesday, March 19, 2025. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results and provide corporate updates.
MediWound (Nasdaq: MDWD), un leader globale nelle terapie enzimatiche di nuova generazione per la riparazione dei tessuti, ha programmato il rilascio dei risultati finanziari del Quarto Trimestre e dell'Anno Completo 2024 per mercoledì 19 marzo 2025. L'azienda ospiterà una conferenza telefonica e una diretta web alle 8:30 ora orientale dello stesso giorno per discutere i risultati finanziari e fornire aggiornamenti aziendali.
MediWound (Nasdaq: MDWD), un líder global en terapias enzimáticas de nueva generación para la reparación de tejidos, ha programado la publicación de sus resultados financieros del Cuarto Trimestre y del Año Completo 2024 para miércoles 19 de marzo de 2025. La compañía llevará a cabo una conferencia telefónica y una transmisión en vivo a las 8:30 a.m. hora del Este ese mismo día para discutir los resultados financieros y proporcionar actualizaciones corporativas.
MediWound (Nasdaq: MDWD), 조직 수리를 위한 차세대 효소 치료의 글로벌 리더는 2024년 4분기 및 전체 연도 재무 결과 발표를 2025년 3월 19일 수요일로 예정했습니다. 회사는 같은 날 동부 표준시 기준 오전 8시 30분에 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜 및 라이브 웹캐스트를 개최할 예정입니다.
MediWound (Nasdaq: MDWD), un leader mondial dans le domaine des thérapies enzymatiques de nouvelle génération pour la réparation des tissus, a programmé la publication de ses résultats financiers pour le Quatrième Trimestre et l'Année Complète 2024 le mercredi 19 mars 2025. L'entreprise tiendra une conférence téléphonique et un webinaire en direct le même jour à 8h30, heure de l'Est, pour discuter des résultats financiers et fournir des mises à jour sur l'entreprise.
MediWound (Nasdaq: MDWD), ein weltweit führendes Unternehmen im Bereich der next-generation enzymatischen Therapeutika zur Gewebereparatur, hat die Veröffentlichung seiner finanziellen Ergebnisse für das Vierte Quartal und das Gesamtjahr 2024 für Mittwoch, den 19. März 2025 angesetzt. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Live-Webcast abhalten, um die finanziellen Ergebnisse zu besprechen und Unternehmensaktualisierungen bereitzustellen.
- None.
- None.
Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time
YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025.
Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.
Dial-in and call details are as follows:
| Conference Call & Webcast Details | ||
| Toll-Free: | 1-833-630-1956 | |
| Israel: | 1-80-921-2373 | |
| International: | 1-412-317-1837 | |
| Webcast: | Click HERE | |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx®, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the currently available
For more information visit www.mediwound.com and follow us on LinkedIn.
| MediWound Contacts: | ||
| Hani Luxenburg | Daniel Ferry | |
| Chief Financial Officer | Managing Director | |
| MediWound Ltd. | LifeSci Advisors, LLC | |
| ir@mediwound.com | daniel@lifesciadvisors.com | |
| Media Contact: | ||
| Ellie Hanson | ||
| FINN Partners for MediWound | ||
| ellie.hanson@finnpartners.com | ||
| +1-929-588-2008 | ||
FAQ
When will MediWound (MDWD) release its Q4 and FY 2024 earnings?
What time is MediWound's (MDWD) Q4 2024 earnings call?
How can investors access MediWound's (MDWD) Q4 2024 earnings call?
What period will MediWound's (MDWD) upcoming earnings report cover?
